Arca
Skip to content

Spinal muscular atrophy

Drug research and approvals for spinal muscular atrophy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 79 studies of spinal muscular atrophy are recruiting on ClinicalTrials.gov, Health Canada has authorized 22 drug trials for it since 2013, FDA has 6 approved and 12 open orphan designations naming it, and the EU has 4 authorised medicines for it.

  • Recruiting worldwide: 79
  • Trials authorized in Canada: 22
  • FDA orphan approvals: 6
  • EU medicines: 4

Recruiting Now

Newest start dates first, of 79 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 22; search them all in Canada trials
May 11, 2026A phase 3, randomized, double-blinded study to evaluate the safety and efficacy of salanersen (biib115) after onasemnogene abeparvovec treatment in infants…SALANERSEN (BIIB115)BiogenPending
Mar 20, 2026An open-label, phase 3 study to evaluate the efficacy and safety of salanersen (biib115) in participants aged 15–60 years with spinal muscular atrophy who are…SALANERSEN (BIIB115)BiogenPending
Dec 15, 2025A phase 2 double-blinded, randomized, placebo-controlled study to assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of…ARGX-119argenx US, Inc.Pending
Dec 20, 2023A phase II, open-label study to investigate the pharmacokinetics and safety, of risdiplam (ro7034067) in infants with spinal muscular atrophyRISDIPLAMRocheClosed
Sep 12, 2023A two-part, seamless, multi-center, randomized, placebo-controlled, double-blind study to investigate the safety, tolerability, pharmacokinetics,…GYM329 (RO7204239) / RISDIPLAMRocheOngoing
Apr 11, 2023A phase 2, randomised, double-blind, placebo-controlled, 2-way crossover study to evaluate the efficacy, safety, and tolerability of nmd670 in ambulatory…NMD670NMD PHARMA A/SClosed
Aug 5, 2022Phase IIIb, open-label, single-arm, multi-center study to evaluate the safety, tolerability and efficacy of oav101 administered intrathecally (1.2 x 1014…ZOLGENSMANovartis Pharmaceuticals CorporationClosed
Apr 20, 2022A long-term extension study of nusinersen (biib058) administered at higher doses in participants with spinal muscular atrophy who previously participated in an…NUSINERSEN (BIIB058)BiogenClosed
Aug 4, 2021An open label study of risdiplam in infants with genetically diagnosed and presymptomatic spinal muscular atrophyRISDIPLAMRocheClosed
Jun 24, 2021A phase IIIb, open-label, single-arm, single-dose, multicenter study to evaluate the safety, tolerability and efficacy of gene replacement therapy with…ZOLGENSMANovartis Pharmaceuticals CorporationOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 18
Sep 11, 2026Isembyldtreatment of spinal muscular atrophy (SMA) in adults and pediatric patients 2 years of age and older who are currently receiving a survival…Scholar RockApproved
Nov 24, 2025Itvismatreatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in survival…Novartis Gene Therapies, Inc.Approved
May 27, 2022EvrysdiTreatment of spinal muscular atrophy (SMA) in pediatric and adult patientsGenentech, Inc., a Member of the Roche GroupApproved
Aug 7, 2020Evrysditreatment of spinal muscular atrophy (SMA) in patients 2 months of age and olderGenentech, Inc., a Member of the Roche GroupApproved
May 24, 2019ZOLGENSMAIndicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in…Novartis Gene Therapies, Inc.Approved
Dec 23, 2016SpinrazaTreatment of spinal muscular atrophy in pediatric and adult patientsBiogen, IncApproved
Nov 10, 2025self-complementary recombinant adeno-associated viral…treatment of spinal muscular atrophy (SMA) in patients 2 years of age and olderBeijing Genecradle Therapeutics Co., Ltd.Designated
Jul 23, 2025pegylated insulin-like growth factor 1 (PEG-IGF1)treatment of spinal muscular atrophy (SMA)Sarcomed ABDesignated
Jan 22, 2024antisense oligonucleotide (ASO) binding SMN2 pre-mRNATreatment of Spinal Muscular AtrophyBiogenDesignated
Dec 16, 2022Taldefgrobep AlfaTreatment of spinal muscular atrophyBiohaven Pharmaceuticals, Inc.Designated
Dec 7, 2021A humanized monoclonal IgG1-based antibody which binds to…Treatment of Spinal Muscular Atrophy (SMA)Genentech Inc.Designated
Nov 24, 2020Single-stranded, non-replicating recombinant…Treatment of spinal muscular atrophy with respiratory distress type 1 (SMARD1)Abigail Wexner Research Institute, Nationwide Children’s HospitalDesignated
Mar 4, 2020Phosphorodiamidate morpholino oligomer (5¿-…Treatment of Spinal Muscular AtrophyShift Pharmaceuticals Holdings, Inc.Designated
May 11, 2017fast skeletal muscle troponin activatorTreatment of spinal muscular atrophyCytokinetics, Inc.Designated
Oct 18, 2011sodium 4-phenylbutyrateTreatment of spinal muscular atrophyGMP-Orphan SASDesignated

Medicines Authorised in the EU

Newest first
Jun 30, 2026Itvismaonasemnogene abeparvovecNovartis Europharm LimitedEMA ↗
Mar 26, 2021EvrysdirisdiplamRoche Registration GmbHEMA ↗
May 18, 2020Zolgensmaonasemnogene abeparvovec · orphanNovartis Europharm LimitedEMA ↗
May 30, 2017Spinrazanusinersen · orphanBiogen Netherlands B.V.EMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.